Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $14.6 million.

  • Fulcrum Therapeutics' Share-based Compensation fell 11.97% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 23.49%. This contributed to the annual value of $14.6 million for FY2024, which is 1.68% down from last year.
  • Fulcrum Therapeutics' Share-based Compensation amounted to $14.6 million in FY2024, which was down 1.68% from $14.8 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Share-based Compensation registered a high of $14.8 million during FY2023, and its lowest value of $7.3 million during FY2020.
  • For the 3-year period, Fulcrum Therapeutics' Share-based Compensation averaged around $14.2 million, with its median value being $14.6 million (2024).
  • In the last 5 years, Fulcrum Therapeutics' Share-based Compensation skyrocketed by 74.01% in 2020 and then dropped by 1.68% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Share-based Compensation (Yearly) stood at $7.3 million in 2020, then soared by 50.61% to $11.1 million in 2021, then rose by 20.60% to $13.3 million in 2022, then rose by 10.88% to $14.8 million in 2023, then decreased by 1.68% to $14.6 million in 2024.